Opioid-Induced Constipation Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight (Albany, US) DelveInsight has launched a new report on "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030".DelveInsight's "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Opioid-Induced Constipation, historical and forecasted epidemiology as well as the Opioid-Induced Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Companies covered:AstraZeneca PlcBausch Health Companies Inc.Daiichi Sankyo Co. Ltd.Ironwood Pharmaceuticals Inc.Mallinckrodt PlcMerck & Co. Inc.Novartis AGPfizer Inc.SHIONOGI Co. Ltd.Takeda Pharmaceutical Co. LtdView Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketRequest free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketOpioid-Induced Constipation Epidemiology  The Opioid-Induced Constipation epidemiology division provide insights about historical and current Opioid-Induced Constipation patient pool and forecasted trend for every seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
Scope of the ReportThe report covers the descriptive overview of Opioid-Induced Constipation, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Opioid-Induced Constipation epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Opioid-Induced Constipation are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Opioid-Induced Constipation market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Opioid-Induced Constipation market View Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-marketRequest free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-market Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract.
The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik.
Opioid-Induced Constipation Market OutlookThe Opioid-Induced Constipation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Opioid-Induced Constipation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Opioid-Induced Constipation Total Market Share (%) Distribution in 2030Opioid-Induced Constipation: Disease Background and Overview5.1.